 |
| Antibodies Market |
The global Antibodies Market is estimated to be valued at US$ 224,083.5 million in 2023 and is expected to exhibit a CAGR of 12.9% over the forecast period
of 2023-2030, as highlighted in a new report published by Coherent Market
Insights.
Market Overview:
The Antibodies Market comprises a range of products that are used in the diagnosis
and treatment of various diseases. Antibodies, also known as immunoglobulins,
are large proteins produced by the immune system to identify and neutralize
foreign substances such as bacteria and viruses. The advantage of using
antibodies in therapy is their ability to specifically target disease-causing
agents while minimizing harm to healthy cells. The need for effective and
targeted therapies has driven the demand for antibody-based treatments in
healthcare settings.
Market Key Trends:
One key trend in the Antibodies Market is the increasing adoption of monoclonal
antibodies (mAbs). Monoclonal antibodies are a class of antibodies that are
derived from a single clone of cells and can be designed to target specific
antigens. These mAbs have shown promising results in the treatment of cancer,
autoimmune diseases, and infectious diseases. The high specificity and
effectiveness of mAbs in targeting disease markers have led to their widespread
use in the healthcare industry. With ongoing research and advancements in
technology, the market for monoclonal antibodies is expected to grow
significantly in the coming years.
Porter’s Analysis:
Threat of New Entrants: The Antibodies
Market Size has a moderate threat of new entrants. While the market is
highly competitive and dominated by key players, the barriers to entry are not
extremely high. However, the established players have a strong presence and
extensive R&D capabilities, which may deter new entrants from gaining
significant market share.
Bargaining Power of Buyers: The bargaining power of buyers in the antibodies
market is moderate. Buyers, such as healthcare providers and pharmaceutical
companies, have a certain level of bargaining power due to the availability of
various antibody products in the market. However, the dominance of key players
and the critical nature of these products limit the buyers' ability to
negotiate favorable terms.
Bargaining Power of Suppliers: The bargaining power of suppliers in the
antibodies market is low. The key players in the market have established
relationships with suppliers and have long-term contracts, ensuring a reliable
supply of raw materials. Additionally, the presence of numerous suppliers
reduces the suppliers' ability to exert significant influence on prices or terms.
Threat of New Substitutes: The threat of new substitutes in the antibodies
market is low. Antibodies are widely regarded as one of the most effective ways
to fight diseases and have a proven track record in the medical field.
Substitutes, such as small molecule drugs or gene therapies, do exist, but they
cannot fully replicate the specificity and efficacy of antibodies.
Competitive Rivalry: The antibodies market is highly competitive, with intense
rivalry among key players. Companies like Novartis AG, F. Hoffmann-La Roche
Ltd., and Johnson & Johnson Services, Inc. dominate the market and
constantly strive to gain a competitive edge through product innovations,
partnerships, and acquisitions. The high level of competition leads to frequent
product launches and advancements in technology, benefiting both the market and
consumers.
Key Takeaways:
The global antibodies market is expected to witness high growth, exhibiting a CAGR of 12.9% over the forecast period
of 2023-2030. This growth can be attributed to the increasing prevalence of
chronic diseases, the rise in investments in biotechnology and pharmaceutical
research, and the growing demand for targeted therapies.
In terms of regional analysis, North America is the fastest-growing and
dominating region in the antibodies market. The region is driven by factors
such as a well-established healthcare infrastructure, increased investment in
R&D activities, and the presence of major pharmaceutical companies.
Key players operating in the antibodies market include Novartis AG, F.
Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda
Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb
Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc.,
Ultragenyx Pharmaceutical Inc., and Kyowa Kirin Co., Ltd. These companies are
focusing on strategic collaborations, product launches, and expansions to
strengthen their market position and cater to the growing demand for antibodies
worldwide.
Read More: https://www.trendingwebwire.com/antibodies-market-witnessing-high-growth-in-global-market/